Rosa Rossling1, Johannes Kurth1, Emily Decelle2, Chin-Lee Wu2, W Scott McDougal2, Leo L. Cheng2
1Charit Universittsmedizin, Berlin, Germany; 2Massachusetts General Hospital, Boston, MA, United States
A 2005 publication on the investigations of human prostate cancer metabolomics led to two major conclusions that metabolomic profiles can differentiate tissue specimens with and without cancer glands, as well as patient pathological stages. However, this study only proposed the metabolomic structure from the analysis of a training cohort and did not evaluate another independent testing cohort. In this study we followed the concepts of previous report and analyzed tissue samples from prostate cancer patients with constructions of training and testing cohorts.